Close this search box.

A national data supplier reviewed PCSK9 inhibitor claims for Medicare, Medicaid, Medicaid managed care, and commercial managed care organizations across the nation from January 2018 through December 2018.

Of national health plans that received at least 3,000 claims for PCSK9 inhibitors, the following had the highest rates of rejection:

Read Report Card | View Maps

Leave a Reply

Your email address will not be published. Required fields are marked *